NFKB1 and posterior cortical atrophy: This is probably due to the systemic toxicity, selectivity, and bioavailability issues that have marred the development of potent, efficacious, and safe small molecule inhibitors to target dysregulated NF-κB expression for the clinical treatment of PCa.